Eisai’s BACE Inhibitor Gets FDA’s Fast-Track Status

Eisai said on November 18 that the US FDA has granted fast track designation for its beta secretase cleaving enzyme (BACE) inhibitor E2609, an investigational Alzheimer’s disease treatment discovered by the Japanese drug maker that is being developed together with...read more